WASHINGTON, June 6, 2018 /PRNewswire/ -- The Antimicrobials
Working Group (AWG) today announced that 13 of its member companies
will present data from their clinical and research programs at the
American Society for Microbiology's ASM Microbe 2018 meeting to be
held June 7-11 in Atlanta, GA.
ASM Microbe showcases the best microbial sciences in the world
and provides a one-of-a-kind forum to explore the complete spectrum
of microbiology from basic science to translation and
application.
"ASM Microbe provides a valuable opportunity for AWG member
companies throughout the antimicrobial drug development arena to
highlight innovation and demonstrate progress in the fight to
defeat drug resistant infections," said Jeffrey Stein, Ph.D., president and chief
executive officer of Cidara Therapeutics and Chairman of the AWG.
"In over 80 presentations and oral sessions, AWG companies will
highlight developments in their clinical and research programs. The
companies of AWG understand and value the importance of gatherings
such as ASM Microbe to share data with peers working in the fragile
antimicrobial field and brainstorm strategies to protect the public
health."
The following AWG member companies will be presenting at ASM
Microbe 2018: Amplyx Pharmaceuticals, Cidara Therapeutics, Inc.
(NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Iterum
Therapeutics plc (NASDAQ: ITRM), Melinta Therapeutics, Inc.
(NASDAQ: MLNT), Motif Bio plc (AIM/NASDAQ: MTFB), Nabriva
Therapeutics Plc (NASDAQ: NBRV), Paratek Pharmaceuticals, Inc.
(NASDAQ: PRTK), SCYNEXIS, Inc. (NASDAQ: SCYX), Spero Therapeutics,
Inc. (NASDAQ: SPRO), T2 Biosystems, Inc. (NASDAQ: TTOO), Theravance
Biopharma, Inc. (NASDAQ: TBPH) and Zavante Therapeutics.
For more information on AWG member company presentations and
access to specific abstracts, please visit:
http://www.antimicrobialsworkinggroup.org/ASMMicrobe2018
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of 17 antimicrobials and diagnostic device companies:
Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc.,
Cidara Therapeutics Inc., ContraFect Corporation, Iterum
Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC,
Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc.,
SCYNEXIS Inc., Spero Therapeutics, Inc., T2 Biosystems Inc.,
Theravance Biopharma U.S. Inc., Viamet, Vical Incorporated, and
Zavante Therapeutics Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-asm-microbe-2018-300660462.html
SOURCE Antimicrobials Working Group (AWG)